Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Nicotinic Acetylcholine Receptor Alpha-7 Subunit (α7 nAChR) is a homopentameric ligand-gated ion channel highly permeable to Ca²⁺ ions. It is expressed in the brain, spleen, lymphocytes, immune cells, endothelial and vascular smooth muscle cells. It mediates fast synaptic transmission and is involved in cognitive processes, neurogenesis, and inflammation modulation. It is a target for cognitive enhancement in Alzheimer's disease and for improving neurocognition in schizophrenia. It also has anti-inflammatory properties and may reduce inflammatory neurotoxicity. Agonists and antagonists are used to modulate its activity.
Upon binding acetylcholine, the receptor undergoes a conformational change that opens its central pore, allowing rapid influx of cations—especially Ca²⁺—leading to depolarization/excitation of neurons or non-neuronal cells. Rapidly desensitizes after activation. Activation on immune cells suppresses pro-inflammatory cytokines.
12 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nicotinic Acetylcholine Receptor Alpha-7 Subunit (α7 nAChR).